The Systemic
Healing Peptide
TB-500 is a synthetic fragment of Thymosin Beta-4 — a naturally occurring 43 amino acid protein found in virtually every cell of the human body, with notably high concentrations in blood platelets and wound fluid. This strategic biological placement is not coincidental: the body pre-positions Thymosin Beta-4 at the precise sites where injury response will be initiated.
Unlike BPC-157, which acts primarily at the site of administration, TB-500 is designed by biology to operate systemically — distributing throughout the bloodstream to coordinate a body-wide repair response. When tissue damage occurs, Thymosin Beta-4 is released from platelets and upregulated at wound sites to orchestrate the cellular machinery of healing.
The synthetic TB-500 fragment preserves the most biologically active region of Thymosin Beta-4 while improving pharmacokinetic properties. Researchers have isolated the key active sequence — the LKKTET motif — as the primary driver of TB-500's cell migration and actin-regulatory effects.
BPC-157 heals where you inject it. TB-500 heals everywhere at once. Different targets, different mechanisms — which is precisely why they are the most potent combination in tissue repair research.
The Actin-Binding Mechanism
TB-500's mechanism is fundamentally distinct from every other healing peptide — it operates at the level of cytoskeletal protein regulation, not growth factor receptor activation.
Five Tissue Systems
TB-500's systemic distribution means it addresses injury across every vascularized tissue type simultaneously. These are the five primary applications documented in research literature.
TB-500 demonstrates particular efficacy in chronic tendinopathy, a condition where local BPC-157 often proves insufficient alone. By distributing systemically, TB-500 reaches tendon tissue throughout the body simultaneously — recruiting fibroblasts and facilitating matrix remodeling in areas that resist targeted injection. The LKKTET motif drives new collagen fiber deposition within degenerative tendon architecture.
Thymosin Beta-4 promotes muscle fiber regeneration through satellite cell proliferation — the precursor cells responsible for muscle repair. In myocardial and skeletal muscle research, TB-500 has been shown to mobilize stem cells from bone marrow to sites of injury. For skeletal muscle, this means accelerated repair of fiber tears and reduced formation of non-functional scar tissue within muscle bellies.
TB-500 has one of the most robust cardiac research profiles of any peptide. In myocardial infarction models, Thymosin Beta-4 reduced infarct size, promoted cardiomyocyte survival, and attenuated post-infarction scar formation. Remarkably, research demonstrated that TB-500 can promote new cardiomyocyte formation from existing cardiac progenitor cells — a process essentially absent in normal adult cardiac tissue.
In CNS injury models, TB-500 has demonstrated neuroprotective effects through suppression of inflammatory mediators that drive secondary neuronal death following initial trauma. Remyelination support — the restoration of the myelin sheath around nerve fibers — has been documented in multiple sclerosis and spinal cord injury research. The peptide promotes oligodendrocyte survival and proliferation, the cells responsible for myelin production.
TB-500 was first studied extensively in wound healing research. It accelerates wound closure by promoting the migration of keratinocytes and fibroblasts to the wound bed — driven by its actin-binding mechanism. Scar formation is reduced through the organized deposition of new collagen fibers rather than the disordered accumulation that characterizes hypertrophic scars. Angiogenesis at the wound site ensures adequate vascular supply for sustained repair.
TB-500 Recovery Timeline
Based on the documented phases of Thymosin Beta-4 activity in tissue repair research. Individual outcomes vary by injury type, chronicity, and dosing protocol.
TB-500 Dosing Protocol
Dosing parameters derived from research literature and published clinical data. All figures reference research models only.
TB-500 vs BPC-157
Often compared, rarely understood. These compounds address fundamentally different biological axes — which is exactly why they produce an additive effect when combined.
TB-500 + BPC-157: The Wolverine Stack
The research community has given a name to the combination of these two compounds: the Wolverine Stack — after the Marvel character whose defining ability is near-instantaneous tissue regeneration regardless of injury type or severity. The name is apt because the two compounds together cover essentially every documented axis of tissue repair.
Apollo Peptide Sciences offers a pre-blended BPC-157 + TB-500 vial at 5mg each — the Wolverine Stack in a single injection.
View BPC-157 + TB-500 Blend